|Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer|
S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ...
Nature 486 (7404), 532-536, 2012
|Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution|
S Misale, F Di Nicolantonio, A Sartore-Bianchi, S Siena, A Bardelli
Cancer discovery 4 (11), 1269-1280, 2014
|Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer|
S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ...
Science translational medicine 6 (224), 224ra26-224ra26, 2014
|Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer|
S Arena, B Bellosillo, G Siravegna, A Martínez, I Cañadas, L Lazzari, ...
Clinical cancer research 21 (9), 2157-2166, 2015
|KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy|
E Valtorta, S Misale, A Sartore‐Bianchi, ID Nagtegaal, F Paraf, ...
International journal of cancer 133 (5), 1259-1265, 2013
|Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer|
M Russo, S Misale, G Wei, G Siravegna, G Crisafulli, L Lazzari, G Corti, ...
Cancer discovery 6 (1), 36-44, 2016
|Stromal microenvironment shapes the intratumoral architecture of pancreatic cancer|
M Ligorio, S Sil, J Malagon-Lopez, LT Nieman, S Misale, M Di Pilato, ...
Cell 178 (1), 160-175. e27, 2019
|Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer|
A Sartore-Bianchi, E Ardini, R Bosotti, A Amatu, E Valtorta, A Somaschini, ...
JNCI: Journal of the National Cancer Institute 108 (1), 2016
|Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers|
S Misale, I Bozic, J Tong, A Peraza-Penton, A Lallo, F Baldi, KH Lin, ...
Nature communications 6 (1), 1-9, 2015
|TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells|
S Hobor, BO Van Emburgh, E Crowley, S Misale, F Di Nicolantonio, ...
Clinical Cancer Research 20 (24), 6429-6438, 2014
|MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations|
S Arena, G Siravegna, B Mussolin, JD Kearns, BB Wolf, S Misale, ...
Science translational medicine 8 (324), 324ra14-324ra14, 2016
|KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition|
S Misale, JP Fatherree, E Cortez, C Li, S Bilton, D Timonina, DT Myers, ...
Clinical Cancer Research 25 (2), 796-807, 2019
|Targeting the CBM complex causes T reg cells to prime tumours for immune checkpoint therapy|
M Di Pilato, EY Kim, BL Cadilha, JN Prüßmann, MN Nasrallah, ...
Nature 570 (7759), 112-116, 2019
|Resistance to TRK inhibition mediated by convergent MAPK pathway activation|
E Cocco, AM Schram, A Kulick, S Misale, HH Won, R Yaeger, P Razavi, ...
Nature medicine 25 (9), 1422-1427, 2019
|STAT3 can serve as a hit in the process of malignant transformation of primary cells|
M Demaria, S Misale, C Giorgi, V Miano, A Camporeale, J Campisi, ...
Cell Death & Differentiation 19 (8), 1390-1397, 2012
|EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer|
V Amodio, R Yaeger, P Arcella, C Cancelliere, S Lamba, A Lorenzato, ...
Cancer Discovery 10 (8), 1129-1139, 2020
|Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer|
K Knickelbein, J Tong, D Chen, YJ Wang, S Misale, A Bardelli, J Yu, ...
Oncogene 37 (33), 4599-4610, 2018
|HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers|
BT Li, F Michelini, S Misale, E Cocco, L Baldino, Y Cai, S Shifman, HY Tu, ...
Cancer discovery 10 (5), 674-687, 2020
|NADPH-diaphorase colocalizes with GPER and is modulated by the GPER agonist G1 in the supraoptic and paraventricular nuclei of ovariectomized female rats|
D Grassi, N Lagunas, H Pinos, GC Panzica, LM Garcia-Segura, P Collado
Neuroendocrinology 104 (1), 94-104, 2017
|Six months neoadjuvant imatinib improves resectability potential of gastric stromal tumors in Egyptian patients|
GM Saied, AM Kensarah
International Journal of Surgery 8 (2), 105-108, 2010